Navigation Links
Medizone Announces a Second Round of Trials Have Begun.
Date:6/3/2009

SAN FRANCISCO, June 3 /PRNewswire-FirstCall/ -- Medizone International, Inc. (Pink Sheets: MZEI) is pleased to announce the commencement of a second series of laboratory trials of the Company's AsepticSure hospital sterilization technology, which is intended to build upon the success of its research to date. Dr. Michael E. Shannon, Director of Medical Affairs for Medizone stated, "Our first round of trials using this technology produced results that exceeded our expectations in demonstrating significant bactericidal effects against C-difficile, E-coli, Pseudomonas aeruginous, MRSA and VRE, the main causative agents of hospital derived nosocomial infections. With the introduction of several new technological developments into this next series of trials, we believe AsepticSure will emerge dominant in the industry not only for the decontamination of hospital facilities but also for applications currently thought to be unassailable."

Medizone anticipates completion of these new studies by early July, whereupon it intends to commence field trials in preparation for marketing later this calendar year. To learn more about these global health concerns the AsepticSure system addresses, please visit the company's web site: www.medizoneint.com. From the home page, go to AsepticSure. The presentation offered is a detailed analysis of the global health problems caused by hospital derived nosocomial infections.

Medizone International, Inc., is a research and development company engaged in developing its' AsepticSure technology to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. If current trials continue to proceed successfully they will be followed by a hospital mock-up and then hospital beta testing of the production prototype. Initial sales are targeted to commence in the 4th quarter of this year.

This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.

    Investor Relations 800-953-3350 / web site: www.medizoneint.com
    E-mail: operations@medizoneint.com


'/>"/>
SOURCE Medizone International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Medizone International, Inc. Announces Strategic Consulting Relationship With TDV Global, Inc.
2. The Canadian Foundation for Global Health Announces a Research and Development Partnership with Medizone International, Inc.
3. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
4. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
5. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
6. HEI, Inc. Announces Sale of RFID Division Assets
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
8. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
9. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
10. Brooke Franchise Corporation Announces Selected July Results
11. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... CA (PRWEB) , ... February 23, 2017 , ... CALNOC, ... FACP, FACMPE, FACPE, will keynote their upcoming conference – Empowerment, Value and Collaboration – ... the chairman and CEO of the Virginia Mason Health System in Seattle since 2000. ...
(Date:2/23/2017)... ... February 23, 2017 , ... Curemark, LLC announced today that ... of CM-AT in children aged 3-8 with Autism, is now enrolling at three new ... children across the United States. , “There are currently no approved drugs that ...
(Date:2/23/2017)... ... ... Thomas Vas-Don suffered from severe injury due to an ... successfully recover. In “ Origin & Insertion Charts for Massage Therapists ” (published by ... massage, anatomy , trigger points and referral pain patterns . , In ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... and lobby of a new healthcare contact center in Georgia, PENETRON Specialty Products ... of the nation’s largest healthcare systems recently invested $51 million to purchase and ...
(Date:2/22/2017)... Raton, FL (PRWEB) , ... February 22, 2017 , ... ... primarily from deer antler velvet, announced its products are coming soon to Amazon.com, the ... Clint and Shelley Thomson as a means to develop an effective natural treatment for ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... February 23, 2017 Persistence ... the global market for intraoperative imaging, excerpts from ... at US$ 513.9 million. According to the report, ... on the grounds of increasing adoption of minimally-invasive ... of diagnostic imaging for neurosurgeries. The world,s leading ...
(Date:2/23/2017)... DUBLIN , Feb 23, 2017 Research ... Prosthetic Devices Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 9.2% over the next ... industry report analyzes the market estimates and forecasts for all the ...
(Date:2/23/2017)... , Feb. 23, 2017 MabVax ... oncology drug development company, announces that it has ... Administration (FDA) authorizing the initiation a Phase I ... for pancreatic cancer. MVT-1075 ( 177 Lu-CHX-A?-DTPA-HuMab5B1) is ... MabVax plans to initiate the phase I clinical ...
Breaking Medicine Technology: